Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Epidemiology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment.
• Statins are commonly used lipid-lowering drugs with potential immunomodulatory effects.
• The interaction between statin use and ICI efficacy in NSCLC remains incompletely understood.

Purpose of the Study:

• To investigate the association between concurrent statin use and mortality outcomes in NSCLC patients receiving ICIs.
• To evaluate the impact of statin use on lung cancer-specific and overall mortality.

Main Methods:

• Retrospective analysis of Medicare beneficiaries aged 65+ diagnosed with NSCLC between 2007-2017.
• Patients treated with an ICI were identified and followed for mortality outcomes.
• Cox models with time-updated statin use and propensity score adjustment were employed to estimate hazard ratios.

Main Results:

• Concurrent statin use with ICIs was associated with a 41% lower risk of lung cancer-specific mortality (HR=0.59).
• Statin use was also linked to a significantly lower risk of overall mortality (HR=0.62).
• These associations remained consistent when analyzing PD-1 inhibitors and different statin types.

Conclusions:

• Concurrent statin use with ICIs appears to be associated with improved survival in older NSCLC patients.
• Further prospective studies and randomized trials are warranted to confirm these findings.
• Future research should explore underlying mechanisms and optimal statin-ICI combinations.